Literature DB >> 32220710

Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2.

Luca Roncati1, Graziana Gallo2, Antonio Manenti2, Beniamino Palmieri2.   

Abstract

Entities:  

Year:  2020        PMID: 32220710      PMCID: PMC7118521          DOI: 10.1016/j.mehy.2020.109686

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


× No keyword cloud information.

Background

In humans the renin-angiotensin system is the hormone system which regulates blood pressure and vascular resistances, as well as electrolytic balance; within this important system, the angiotensin-converting enzyme (ACE), present on the surface of vascular endothelial cells, in particular those of the lungs, is deputed to the conversion of angiotensin I to angiotensin II (AII), a potent vasoconstrictive peptide [1]. For this, both ACE and AII have been widely exploited as pharmacological targets in the treatment of hypertension, heart failure or diabetic nephropathy by means of ACE inhibitors and AII receptor antagonists, respectively [1]. In addition, homologous ACE2 receptors have been identified on the oral mucosa, in type-II pneumocytes, along the intestine and on the kidney and heart endothelia [1], [2]; these receptors have been found overexpressed in course of ACE inhibitors and AII receptor antagonists administration in murine models [3], [4].

Hypothesis

Surprisingly, the surface spike proteins of the ‘severe-acute-respiratory-syndrome-coronavirus-2′ (SARS-CoV-2), the etiological agent of the ongoing ‘coronavirus disease 2019’ (COVID-19), are able to bind the ACE2 receptors [2]. Therefore, a hypothesis arises: could a chronic therapeutic assumption of ACE inhibitors or AII receptor antagonists have induced several elderly and middle-aged patients to be more vulnerable to the virus by upregulating ACE2 receptors? If we translate the murine model to the human cells, the expected result would be that shown in the figure (Fig. 1 ). In our opinion, during the COVID-19 pandemic, it would be more prudent to replace these drugs, when possible, with calcium channel blockers, adrenergic receptor blockers, diuretics or vasodilators.
Fig. 1

After a chronic assumption of ACE inhibitors and AII receptor antagonists a normal cell (on the left) could be hypothetically rearranged into one with higher expression of ACE2 receptors (on the right), so turning particularly receptive and vulnerable to SARS-CoV-2.

After a chronic assumption of ACE inhibitors and AII receptor antagonists a normal cell (on the left) could be hypothetically rearranged into one with higher expression of ACE2 receptors (on the right), so turning particularly receptive and vulnerable to SARS-CoV-2.

Sources of support in the form of grants

None.

Conflict of interest statement

No conflict of interest.
  3 in total

Review 1.  Angiotensin-converting enzyme 2--a new cardiac regulator.

Authors:  Manfred Boehm; Elizabeth G Nabel
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

Review 2.  Effect of age on cardiac excitation-contraction coupling.

Authors:  Elias Fares; Susan E Howlett
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-08-04       Impact factor: 2.557

3.  Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

Authors:  Carlos M Ferrario; Jewell Jessup; Mark C Chappell; David B Averill; K Bridget Brosnihan; E Ann Tallant; Debra I Diz; Patricia E Gallagher
Journal:  Circulation       Date:  2005-05-16       Impact factor: 29.690

  3 in total
  15 in total

1.  Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications.

Authors:  Loredana Raciti; Francesca Antonia Arcadi; Rocco Salvatore Calabrò
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

2.  High density of IgG4-secreting plasma cells in the fibrotic tissue from a surgically resected tracheal ring impaired by complex subglottic stenosis post-tracheostomy as immune expression of a Th2 response due to severe COVID-19.

Authors:  Luca Roncati; Giuliano Bergonzini; Beatrice Lusenti; Vincenzo Nasillo; Ambra Paolini; Giuliana Zanelli; Stefania Corrado
Journal:  Ann Hematol       Date:  2020-08-28       Impact factor: 3.673

3.  Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?

Authors:  Gokhan Sargin; Sare İlknur Yavaşoğlu; Irfan Yavasoglu
Journal:  Med Hypotheses       Date:  2020-04-22       Impact factor: 1.538

4.  The puzzle of sharing bio-molecular targets between coronaviruses and mediators of the cardiovascular system in humans: Looking for plausible hypotheses.

Authors:  Michele M Ciulla
Journal:  Med Hypotheses       Date:  2020-04-27       Impact factor: 1.538

5.  COVID-19 vaccine and boosted immunity: Nothing ad interim to do?

Authors:  Luca Roncati; Maria Vadalà; Veronica Corazzari; Beniamino Palmieri
Journal:  Vaccine       Date:  2020-10-09       Impact factor: 3.641

Review 6.  The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents.

Authors:  Gustavo R Villas-Boas; Vanessa C Rescia; Marina M Paes; Stefânia N Lavorato; Manoel F de Magalhães-Filho; Mila S Cunha; Rafael da C Simões; Roseli B de Lacerda; Renilson S de Freitas-Júnior; Bruno H da S Ramos; Ana M Mapeli; Matheus da S T Henriques; William R de Freitas; Luiz A F Lopes; Luiz G R Oliveira; Jonatas G da Silva; Saulo E Silva-Filho; Ana P S da Silveira; Katyuscya V Leão; Maria M de S Matos; Jamille S Fernandes; Roberto K N Cuman; Francielli M de S Silva-Comar; Jurandir F Comar; Luana do A Brasileiro; Jussileide N Dos Santos; Silvia A Oesterreich
Journal:  Molecules       Date:  2020-09-07       Impact factor: 4.411

7.  HSV1 viremia with fulminant hepatitis as opportunistic sequela in severe COVID-19.

Authors:  Luca Roncati; Antonio Manenti; Luca Fabbiani; Claudia Malagoli; Vincenzo Nasillo; Beatrice Lusenti; Massimo Lupi; Giuliana Zanelli; Tiziana Salviato; Matteo Costantini; Tommaso Trenti; Antonio Maiorana
Journal:  Ann Hematol       Date:  2021-01-18       Impact factor: 3.673

8.  Aortitis in COVID-19.

Authors:  Pravash Dhakal; Sushmita Khadka; Jackie A Clowes; Raja Chandra Chakinala
Journal:  IDCases       Date:  2021-03-10

Review 9.  Severe Acute Respiratory Syndrome-Associated Coronavirus 2 Infection and Organ Dysfunction in the ICU: Opportunities for Translational Research.

Authors:  Philip A Verhoef; Sujatha Kannan; Jamie L Sturgill; Elizabeth W Tucker; Peter E Morris; Andrew C Miller; Travis R Sexton; Jay L Koyner; Rana Hejal; Scott C Brakenridge; Lyle L Moldawer; Richard S Hotchkiss; Teresa M Blood; Monty B Mazer; Scott Bolesta; Sheila A Alexander; Donna Lee Armaignac; Steven L Shein; Christopher Jones; Caroline D Hoemann; Allan Doctor; Stuart H Friess; Robert I Parker; Alexandre T Rotta; Kenneth E Remy
Journal:  Crit Care Explor       Date:  2021-03-12

10.  SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.

Authors:  Michele M Ciulla
Journal:  Hypertens Res       Date:  2020-06-10       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.